All In Biotech

Drug Trial Radar · NCT07011043

A Phase 1b Study of Budoprutug in Systemic Lupus Erythematosus (SLE)

A Phase 1b Open-Label, Single Ascending Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Budoprutug (TNT119) in Adult Subjects With Systemic Lupus Erythematosus (SLE)

Last checked: Nov 19, 2026Latest source record: Mar 27, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Recruiting

Status

Recruiting

Enrollment

30

Planned (sponsor's estimate)

Start

Jul 10, 2025

Primary completion

Apr 2027

Study completion Apr 2027

Sponsor

Lead sponsor
Climb Bio, Inc.Industry
Sponsor type
Industry
First posted
Jun 8, 2025

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Non randomized
Model
Sequential
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years, up to 65 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The main objective is to assess the safety and tolerability of budoprutug in adults with SLE. Pharmacokinetics, pharmacodynamics, and preliminary clinical efficacy will also be assessed.

Conditions

  • Systemic Lupus Erythematosus

Interventions

  • BudoprutugDrug

    Single IV dose of study product on Day 1 of study

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Incidence of Treatment-Emergent Adverse Events (TEAEs)Time frame: Up to Week 24
  2. Incidence of Clinical Laboratory AbnormalitiesTime frame: Up to Week 24
  3. Change from Baseline in Systolic Blood PressureTime frame: Up to Week 24
  4. Change from Baseline in Diastolic Blood PressureTime frame: Up to Week 24
  5. Change from Baseline in Heart RateTime frame: Up to Week 24
  6. Change from Baseline in Respiratory RateTime frame: Up to Week 24
  7. Change from Baseline in Body TemperatureTime frame: Up to Week 24
  8. Change from Baseline in PR IntervalTime frame: Up to Week 24
  9. Change from Baseline in QRS DurationTime frame: Up to Week 24
  10. Change from Baseline in QT IntervalTime frame: Up to Week 24
  11. Change from Baseline in QTc IntervalTime frame: Up to Week 24

Locations

18 sites in 8 countries. Site status is shown where the registry gives one.

  • Climb Bio Investigative Site #100104

    Allen, Texas · Recruiting

  • Climb Bio Investigative Site #100101

    San Antonio, Texas · Recruiting

  • Climb Bio Investigative Site# 359101

    Plovdiv, Bulgaria · Recruiting

  • Climb Bio Investigative Site# 359102

    Sofia, Bulgaria · Recruiting

  • Climb Bio Investigative Site #995102

    Tbilisi, Georgia · Recruiting

  • Climb Bio Investigative Site #995101

    Tbilisi, Georgia · Recruiting

  • Climb Bio Investigative Site# 300102

    Exochi, Thessaloniki, Greece · Recruiting

  • Climb Bio Investigative Site# 300103

    Thessaloniki, Thessaloniki, Greece · Recruiting

  • Climb Bio Investigative Site #100103

    Caguas, Puerto Rico · Recruiting

  • Climb Bio Investigative Site# 400101

    Cluj-Napoca, Romania · Recruiting

  • Climb Bio Investigative Site# 340102

    A Coruña, Spain · Recruiting

  • Climb Bio Investigative Site# 340101

    Sabadell, Barcelona, Spain · Recruiting

  • Climb Bio Investigative Site #380102

    Ivano-Frankivsk, Ukraine · Recruiting

  • Climb Bio Investigative Site #380103

    Kyiv, Ukraine · Recruiting

  • Climb Bio Investigative Site #380106

    Kyiv, Ukraine · Recruiting

  • Climb Bio Investigative Site #380101

    Ternopil, Ukraine · Recruiting

  • Climb Bio Investigative Site #380104

    Vinnytsia, Ukraine · Recruiting

  • Climb Bio Investigative Site #380105

    Vinnytsia, Ukraine · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.